This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function. This innovative approach offers a safe, cost-effective, and easily implementable therapeutic strategy for older adults at high risk for Alzheimer's dementia, especially APOE4 carriers, addressing a critical need given the limited cognitive benefits and significant adverse events of current amyloid-clearing drugs in this population.
Age 60 years or older
Have amnestic Mild Cognitive Impairment (MCI) - memory problems that do not interfere with daily life.
Carry at least one APOE4 gene allele (determined by a blood test).
Be fluent in English or Spanish.
A diagnosis of dementia or any other brain disease that significantly affects thinking or memory (e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, traumatic brain injury).
History of stroke or other major neurological condition.
Short life expectancy due to end-stage disease or other serious medical condition.
Active cancer treatment that could interfere with study participation.
Michal Schnaider Beeri, Ph.D.
Lead sponsor
Rutgers, The State University of New Jersey
Sponsor institution